Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody

Journal of Infectious Diseases

Volumn 201, Issue 10, 2010, Pages 1481-1487

  Jacobson, Jeffrey M ^a   Thompson, Melanie A ^b   Lalezari, Jacob P ^c   Saag, Michael S ^d   Zingman, Barry S ^e   D'Ambrosio, Paul ^e   Stambler, Nancy ^f   Rotshteyn, Yakov ^f   Marozsan, Andre J ^f   Maddon, Paul J ^f   Morris, Stephen A ^f   Olson, William C ^f  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b AIDS Research Consortium of Atlanta   (United States)

^c Quest Clinical Research   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e MONTEFIORE MEDICAL CENTER   (United States)

^f A Subsidiary of Lantheus Holdings   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; PRO 140; VIRUS RNA; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; MONOCLONAL ANTIBODY;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; DRUG TOLERANCE; FEMALE; HEADACHE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERTENSION; IMMUNE DEFICIENCY; LYMPHADENOPATHY; LYMPHOCYTE COUNT; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIRUS LOAD; DRUG ADMINISTRATION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MIDDLE AGED; MULTICENTER STUDY; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; ANTIBODIES, MONOCLONAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV ANTIBODIES; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED;

EID: 77951916324     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/652190     Document Type: Article

References (40)

1. Bhaskaran K, Hamouda O, Sannes M, et al. Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA 2008; 300(l): 51-59. (Pubitemid 351920404)
2. Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008; 372(9635): 293-299.
3. Effros RB, Fletcher CV, Gebo K, et al. Aging and infectious diseases: workshop on HIV infection and aging: what is known and future research directions. Clin Infect Dis 2008; 47(4): 542-553.
4. Weber R, Sabin CA, Friis-Moller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006; 166(15): 1632-1641.
5. Mondy K, Tebas R Cardiovascular risks of antiretroviral therapies. Annu Rev Med 2007; 58: 141-155. (Pubitemid 46706506)
6. Robertson KR, Smurzynski M, Parsons TD, et al. The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS 2007; 21(14): 1915-1921. (Pubitemid 47329768)
7. Lederman MM, Penn-Nicholson A, Cho M, Mosier D. Biology of CCR5 and its role in HIV infection and treatment. JAMA 2006; 296(7): 815-826. (Pubitemid 44223105)
8. Dean M, Carrington M, Winkler C, et al. Genetic restriction of HIV1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene: Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 1996; 273(5283): 1856-1862.
9. Moyle GJ, Wildfire A, Mandalia S, et al. Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. J Infect Dis 2005; 191(6): 866-872. (Pubitemid 40349800)
10. Wilkin TJ, Su Z, Kuritzkes DR, et al. HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. Clin Infect Dis 2007; 44(4): 591-595. (Pubitemid 46233265)
11. Brumme ZL, Goodrich J, Mayer HB, et al. Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of anti retroviral-naive individuals. J Infect Dis 2005; 192(3): 466-474. (Pubitemid 41023125)
12. Gulick RM, Lalezari J, Goodrich J, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008; 359(14): 1429-1441.
13. Vicriviroc in HIV-treatment experienced subjects (study P04889AM7). ClinicalTrials.gov Web site. http://www.clinicaltrials.gov/ct2/show/NCT00474370. First received 15 May 2007. Last updated 4 March 2010. Accessed 6 August 2009.
14. Vicriviroc in HIV-treatment experienced subjects (study P04405AM4). ClinicalTrials.gov Web site. http://www.clinicaltrials.gov/ct2/show/NCT00523211. First received 30 August 2007. Last updated 4 March 2010. Accessed 6 August 2009.
15. Murga J, Franti M, Pevear DC, Maddon PJ, Olson WC. Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1. Antimicrob Agents Chemother 2006; 50(10): 3289-3296. (Pubitemid 44527500)
16. Trkola A, Ketas TJ, Nagashima KA, et al. Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140. J Virol 2001; 75(2): 579-588. (Pubitemid 32037260)
17. Jacobson JM, Saag MS, Thompson MA, et al. Antiviral activity of singledose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults. J Infect Dis 2008; 198(9): 1345-1352.
18. Fatkenheuer G, Pozniak AL, Johnson MA, et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med 2005; 11(11): 1170-1172.
19. Schurmann D, Fatkenheuer G, Reynes J, et al. Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults. AIDS 2007; 21(10): 1293-1299. (Pubitemid 46883483)
20. LalezariJ,ThompsonM,KumarP,etal.Antiviralactivityandsafetyof873140, anovelCCR5antagonist,duringshort-term monotherapyinHIV-infectedadults. AIDS2005;19(14):1443-1448.(Pubitemid41400688)
21. Polis MA, Sidorov IA, Yoder C, et al. Correlation between reduction in plasma HIV-1 RNA concentration 1 week after start of antiretroviral treatment and longer-term efficacy. Lancet 2001; 358(9295): 1760-1765. (Pubitemid 33153000)
22. Kuritzkes DR, Ribaudo HJ, Squires KE, et al. Plasma HIV-1 RNA dynamics in antiretroviral-naive subjects receiving either triple-nucleoside or efavirenz-containing regimens: ACTG A5166s. J Infect Dis 2007; 195(8): 1169-1176.
23. Maitland D, Jackson A, Osorio J, Mandalia S, Gazzard BG, Moyle GJ. Switching from twice-daily abacavir and lamivudine to the once-daily fixed-dose combination tablet of abacavir and lamivudine improves patient adherence and satisfaction with therapy. HIV Med 2008; 9(8): 667-672.
24. Boyle BA, Jayaweera D, Witt MD, Grimm K, Maa JF, Seekins DW. Randomization to once-daily stavudine extended release/lamivudine/ efavirenz versus a more frequent regimen improves adherence while maintaining viral suppression. HIV Clin Trials 2008; 9(3): 164-176. (Pubitemid 351892870)
25. Molina JM, Podsadecki TJ, Johnson MA, et al. A lopinavir/ritonavirbased once-daily regimen results in better compliance and is noninferior to a twice-daily regimen through 96 weeks. AIDS Res Hum Retroviruses 2007; 23(12): 1505-1514.
26. Hammer SM, Eron JJ Jr, Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008; 300(5): 555-570.
27. Porter CJ, Charman WN. Transport and absorption of drugs via the lymphatic system. Adv Drug Deliv Rev 2001; 50(1-2): 1-2.
28. Moore JP, Kuritzkes DR. A piece de resistance: how HIV-1 escapes small molecule CCR5 inhibitors. Curr Opin HIV AIDS 2009; 4(2): 118-124.
29. Tsibris AM, Korber B, Arnaout R, et al. Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo. PLoS ONE 2009; 4(5): e5683.
30. Westby M, Lewis M, Whitcomb J, et al. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J Virol 2006; 80(10): 4909-4920.
31. Lewis M, Simpson P, Fransen S, et al. CXCR4-using virus detected in patients receiving maraviroc in the phase III studies MOTIVATE 1 and 2 originates from a pre-existing minority of CXCR4-using virus. Antivir Ther 2007; 12: S65.
32. Marozsan AJ, Parsons T, Huang W, et al. Clonal analysis of HIV-1 coreceptor tropism change following treatment with PRO 140, a CCR5 monoclonal antibody. Paper presented at: 48th Annual ICAAC/IDSA 46th Annual Meeting (abstract H-1218); 25-28 October 2008; Washington, DC.
33. Saag MS, Emini EA, Laskin OL, et al. A short-term clinical evaluation of L-697,661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase. L-697, 661 Working Group. N Engl J Med 1993; 329(15): 1065-1072.
34. Richman DD, Havlir D, Corbeil J, et al. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol 1994; 68(3): 1660-1666.
35. HavlirDV,EastmanS,GamstA,RichmanDD.Nevirapine- resistanthumanimmunodeficiencyvirus:kineticsofreplicationand estimatedprevalenceinuntreatedpatients.JVirol1996;70(11):7894-7899. (Pubitemid26339097)
36. Vazquez-Rosales G, Garcia Lerma JG, Yamamoto S, et al. Rapid screening of phenotypic resistance to nevirapine by direct analysis of HIV type 1 reverse transcriptase activity in plasma. AIDS Res Hum Retroviruses 1999; 15(13): 1191-1200. (Pubitemid 29411804)
37. Chi BH, Sinkala M, Mbewe F, et al. Single-dose tenofovir and emtricitabine for reduction of viral resistance to non-nucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomised trial. Lancet 2007; 370(9600): 1698-1705.
38. Darwich L, Esteve A, Ruiz L, Bellido R, Clotet B, Martinez-Picado J. Variability in the plasma concentration of efavirenz and nevirapine is associated with genotypic resistance after treatment interruption. Antivir Ther 2008; 13(7): 945-951.
39. Ochs HD, Gupta S, Kiessling P, Nicolay U, Berger M. Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. J Clin Immunol 2006; 26(3): 265-273. (Pubitemid 43901655)
40. Gardulf A, Andersen V, Bjorkander J, et al. Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs. Lancet 1995; 345(8946): 365-369.